Investor Presentaiton
Innovative R&D - License- In & Out
Maximize product value
AkynzeoⓇ
License In Granted with exclusive right to
Cases
I
commercialize Akynzeo®, AloxiⓇ
i and Anamorelin in Chinese
Mainland, Hong Kong region and
Macau region
#HELSINN
Furmonertinib
Granted with
exclusive right to
commercialize
furmonertinib in
broad region
•艾力斯
I
OtezlaⓇ & ParsabivⓇ
¦¦ Granted with exclusive right to
I
commercialize 2 innovative
! medicines, OtezlaⓇ and
ParsabivⓇ, in Chinese
Mainland
AMGEN
Azvudine
Entered into the strategic collaboration
with GENUINE regarding Azvudine,
the first domestic oral small molecule
drug for COVID-19 treatment GENUINE
approved in China
热烈
Maximize
Product Value
2020/10
2021/10
2022/5
2022/6
2022/7
i BCL-2 inhibitor FCN-338
License Out Granted Lilly to develop,
Cases
manufacture and commercialize
BCL-2 inhibitor FCN-338 in regions
! except Chinese Mainland, Hong
Kong and Macau in October 2020;
Lily shall pay up to USD440 millionnely
ה
Rituximab, Trastuzumab and
Bevacizumab
Granted Eurofarma to develop,
! manufacture and commercialize Rituximab,
Trastuzumab and Bevacizumab in 16 Latin
American countries; Eurofarma shall pay
up to USD50.5 million
eurofarma
22
your life moves ours
ה
ון
T
Pertuzumab & Denosumab I
Granted Organon exclusive
right to commercialize
I
Pertuzumab and Denosumab
in ex-China countries and
regions. Organon shall pay up
to USD541 million ORGANON
I
IView entire presentation